Pharmaceutical companies invest heavily in drug development, with successful drugs generating substantial sales due to patent protection. However, once patents expire, generic alternatives emerge, leading to a significant drop in sales, known as the “patent cliff.” Bristol Myers Squibb (NYSE: BMY) is currently trading over 25% below its peak due to this impending patent cliff. Investors may consider whether this dip presents a buying opportunity.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
